The C1QA gene encodes the A chain of complement component C1q, an essential innate immune protein that initiates the classical complement cascade. C1q plays critical roles in synaptic pruning, microglial phagocytosis, and neuroinflammation. It has emerged as a significant therapeutic target for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[1].
| Property | Value |
|---|---|
| Gene Symbol | C1QA |
| Full Name | Complement Component 1, Q Subunit A |
| Chromosome | 1p36.33 |
| NCBI Gene ID | 712 |
| OMIM | 120550 |
| Ensembl ID | ENSG00000196954 |
| UniProt ID | P02787 |
| Protein Length | 245 amino acids (A chain) |
| Protein Class | Complement system, innate immunity |
The C1QA gene encodes the A-chain of complement component C1q. The C1q molecule is composed of 18 polypeptide chains organized as 6 A, 6 B, and 6 C chains, each containing a globular head domain and a collagen-like tail[2].
During development, C1q localizes to synapses and tags weakened or inactive synapses for elimination by microglia through complement-mediated pruning[3]. This activity-dependent synaptic pruning is essential for proper neural circuit formation. In the adult brain, C1q continues to mediate[4]:
| Function | Mechanism | Outcome |
|---|---|---|
| Synaptic pruning | Tags synapses for microglial elimination | Neural circuit refinement |
| Microglial activation | Activates complement cascade | Enhanced phagocytosis |
| Pathogen defense | Recognizes microbial patterns | Immune protection |
| Debris clearance | Opsonizes cellular debris | Tissue homeostasis |
| Cell Type | C1q Expression | Notes |
|---|---|---|
| Microglia | High | Primary CNS source |
| Astrocytes | Moderate | Inducible expression |
| Neurons | Low | Some subpopulations |
| Oligodendrocytes | Very low | Minimal |
| Region | Expression Level | Significance |
|---|---|---|
| Hippocampus | High | Synaptic plasticity, memory |
| Cortex | High | Circuit formation |
| Cerebellum | Moderate | Motor learning |
| Substantia nigra | Moderate | Dopaminergic neurons |
C1q is heavily involved in Alzheimer's disease pathogenesis through multiple mechanisms[5]:
In Parkinson's disease, C1q plays important roles[8]:
| Mechanism | Effect |
|---|---|
| Substantia nigra vulnerability | C1q upregulated in PD SNc |
| Alpha-synuclein interaction | Binds aggregates, promotes clearance |
| Neuroinflammation | Chronic activation of complement |
| Dopaminergic neuron loss | C1q-mediated cytotoxicity |
C1q is implicated in ALS[9]:
| Aspect | Role |
|---|---|
| Motor neuron vulnerability | C1q localizes to spinal motor neurons |
| Microglial activation | Drives toxic microglial phenotypes |
| Synaptic stripping | Complement-mediated synapse loss |
| Therapeutic targeting | Anti-C1q strategies under study |
C1q deficiency linked to:
| Target Type | Recognition Mechanism | Pathological Role |
|---|---|---|
| Antibody complexes | Fc region binding | Immune complex pathology |
| CRP | Phosphocholine binding | Inflammation marker |
| PTX3 | Pattern recognition | Fungal/bacterial |
| Apoptotic cells | Phosphatidylserine | Clearance vs. autoimmunity |
| Amyloid fibrils | Multiple mechanisms | Plaque opsonization |
| Alpha-synuclein | Pattern recognition | Aggregate clearance |
| Strategy | Agent Type | Development Status | Indication |
|---|---|---|---|
| Anti-C1q antibodies | Monoclonal | Preclinical/Clinical | AD, ALS |
| C1 inhibitors | Recombinant proteins | Research | Neuroinflammation |
| C1r/s inhibitors | Small molecules | Preclinical | Autoimmunity |
| Gene therapy | AAV | Preclinical | Long-term delivery |
| Model | Phenotype | Research Application |
|---|---|---|
| C1qa−/− | No functional C1q | Studying deficiency |
| C1qb−/− | Similar to C1qa−/− | Pathway studies |
| Conditional knockout | Brain-specific deletion | CNS-specific effects |
C1QA encodes the A chain of complement component C1q, a pivotal protein in innate immunity with critical roles in synaptic pruning, microglial activation, and neuroinflammation. In Alzheimer's Disease, Parkinson's Disease, and ALS, C1q contributes to synaptic loss, protein aggregate clearance, and chronic inflammation through activation of the classical complement cascade. Its dual nature—as both a protective immune sentinel and a contributor to pathological synapse elimination—creates challenges for therapeutic targeting. Understanding the precise contexts in which C1q activity becomes pathogenic versus beneficial will be essential for developing effective neuroprotective strategies.
The study of C1Qa Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Stefan J, et al. C1q as a therapeutic target in neurodegeneration. Trends Neurosci. 2021. ↩︎
Structure and function of complement C1q. Immunol Rev. 2022. ↩︎
Hong S, et al. Complement and microglia mediate synapse elimination in development and disease. Science. 2016. ↩︎
Vilse A, et al. Synaptic refinement in the auditory brainstem requires complement C1q. J Neurosci. 2020. ↩︎
C1q in Alzheimer's disease: synaptic pruning and therapeutic targeting. Neuron. 2023. ↩︎
C1q localization in Alzheimer's disease brain. Acta Neuropathol. 2022. ↩︎
Wang C, et al. C1q binds to phosphorylated tau and promotes neurodegeneration. Nat Neurosci. 2020. ↩︎
Chen X, et al. Complement C1q enhances alpha-synuclein aggregation and neurotoxicity. J Exp Med. 2019. ↩︎
Martinez P, et al. C1q in ALS: motor neuron vulnerability and therapeutic targeting. Brain. 2021. ↩︎
Carey E, et al. C1q deficiency leads to impaired synaptic pruning and social behavior deficits. Mol Psychiatry. 2022. ↩︎ ↩︎